Regulation of ABC membrane transporters in glial cells: Relevance to the pharmacotherapy of brain HIV-1 infection

GLIA

Volumn 56, Issue 16, 2008, Pages 1711-1735

  Ronaldson, Patrick T ^a   Persidsky, Yuri ^b   Bendayan, Reina ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

ABC transporters; Antiretroviral drugs; Astrocytes; HIV 1 encephalitis; Microglia

Indexed keywords

ABC TRANSPORTER; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD BRAIN BARRIER; BRAIN; CELL MEMBRANE; DRUG EFFECT; GLIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; REVIEW; VIROLOGY;

AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BLOOD-BRAIN BARRIER; BRAIN; CELL MEMBRANE; HIV-1; HUMANS; NEUROGLIA;

EID: 62149143407     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.20725     Document Type: Article

References (279)

1. Adamson DC, Wildemann B, Sasaki M, Glass JD, McArthur JC, Christov VI, Dawson TM, Dawson VL. 1996. Immunologic NO synthase: Elevation in severe AIDS dementia and induction by HIV-1 gp41. Science 274:1917-1921.
2. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE. 2007. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789-1799.
3. Asensio VC, Campbell IL. 1999. Chemokines in the CNS: Plurifunctional mediators in diverse states. Trends Neurosci 22:504-512.
4. Assem M, Schuetz EG, Leggas M, Sun D, Yasuda K, Reid G, Zelcer N, Adachi M, Strom S, Evans RM, Moore DD, Borst P, Schuetz JD. 2004. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem 279:22250-22257.
5. Babakhanian K, Bendayan M, Bendayan R. 2007. Localization of P-glycoprotein at the nuclear envelope of rat brain cells. Biochem Biophys Res Commun 361:301-306.
6. Baldwin AS Jr. 1996. The NF-jB, I jB proteins: New discoveries and insights. Annu Rev Immunol 14:649-683.
7. Ballerini P, Di Iorio P, Ciccarelli R, Nargi E, D'Alimonte I, Traversa U, Rathbone MP, Caciagli F. 2002. Glial cells express multiple ATP binding cassette proteins which are involved in ATP release. Neuroreport 13:1789-1792.
8. Bauer B, Hartz AM, Fricker G, Miller DS. 2004. Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol 66:413-419.
9. Bauer B, Hartz AM, Miller DS. 2007. Tumor necrosis factor a and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol Pharmacol 71:667-675.
10. Beaulieu E, Demeule M, Ghitescu L, Beliveau R. 1997. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem J 326 (Part 2):539-544.
11. Bendayan R, Lee G, Bendayan M. 2002. Functional expression and localization of P-glycoprotein at the blood brain barrier. Microsc Res Tech 57:365-380.
12. Bendayan R, Ronaldson PT, Gingras D, Bendayan M. 2006. In situ localization of P-glycoprotein (ABCB1) in human and rat brain. J Histochem Cytochem 54:1159-1167.
13. Bertilsson PM, Olsson P, Magnusson KE. 2001. Cytokines influence mRNA expression of cytochrome P450 3A4 and MDRI in intestinal cells. J Pharm Sci 90:638-646.
14. Bezzi P, Domercq M, Brambilla L, Galli R, Schols D, De Clercq E, Vescovi A, Bagetta G, Kollias G, Meldolesi J, Volterra A. 2001. CXCR4-activated astrocyte glutamate release via TNFa: Amplification by microglia triggers neurotoxicity. Nat Neurosci 4:702-710.
15. Bhat NR, Zhang P, Lee JC, Hogan EL. 1998. Extracellular signal-regulated kinase and p38 subgroups of mitogen-activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis factor-a gene expression in endotoxin-stimulated primary glial cultures. J Neurosci 18:1633-1641.
16. Blokzijl H, Vander BS, Bok LI, Libbrecht L, Geuken M, van den Heuvel FA, Dijkstra G, Roskams TA, Moshage H, Jansen PL, Faber KN. 2007. Decreased P-glycoprotein (P-gp/MDR1) expression in inflamed human intestinal epithelium is independent of PXR protein levels. Inflamm Bowel Dis 13:710-720.
17. Bonwetsch R, Croul S, Richardson MW, Lorenzana C, Valle LD, Sverstiuk AE, Amini S, Morgello S, Khalili K, Rappaport J. 1999. Role of HIV-1 Tat and CC chemokine MIP-1a in the pathogenesis of HIV associated central nervous system disorders. J Neurovirol 5:685-694.
18. Borst P, Evers R, Kool M, Wijnholds J. 2000. A family of drug transporters: The multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295-1302.
19. Brack-Werner R. 1999. Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis. AIDS 13:1-22.
20. Brahmachari S, Fung YK, Pahan K. 2006. Induction of glial fibrillary acidic protein expression in astrocytes by nitric oxide. J Neurosci 26:4930-4939.
21. Breedveld P, Beijnen JH, Schellens JH. 2006. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 27:17-24.
22. Brenneman DE, Westbrook GL, Fitzgerald SP, Ennist DL, Elkins KL, Ruff MR, Pert CB. 1988. Neuronal cell killing by the envelope protein of HIV, its prevention by vasoactive intestinal peptide. Nature 335:639-642.
23. Buckingham RE, Al-Barazanji KA, Toseland CD, Slaughter M, Connor SC, West A, Bond B, Turner NC. 1998. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 47:1326-1334.
24. Budka H. 1991. Neuropathology of human immunodeficiency virus infection. Brain Pathol 1:163-175.
25. Bukrinsky MI, Sharova N, Dempsey MP, Stanwick TL, Bukrinskaya AG, Haggerty S, Stevenson M. 1992. Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc Natl Acad Sci USA 89:6580-6584.
26. Canki M, Potash MJ, Bentsman G, Chao W, Flynn T, Heinemann M, Gelbard H, Volsky DJ. 1997. Isolation and long-term culture of primary ocular human immunodeficiency virus type 1 isolates in primary astrocytes. J Neurovirol 3:10-15.
27. Cavalcanti RB, Raboud J, Shen S, Kain KC, Cheung A, Walmsley S. 2007. A randomized, placebo-controlled trial of rosiglitazone for HIVrelated lipoatrophy. J Infect Dis 195:1754-1761.
28. Ceckova-Novotna M, Pavek P, Staud F. 2006. P-glycoprotein in the placenta: Expression, localization, regulation and function. Reprod Toxicol 22:400-410.
29. Chambers TC, Pohl J, Raynor RL, Kuo JF. 1993. Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase C. J Biol Chem 268:4592-4595.
30. Chandler B, Almond L, Ford J, Owen A, Hoggard P, Khoo S, Back D. 2003. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr 33:551-556.
31. Chauhan A, Hahn S, Gartner S, Pardo CA, Netesan SK, McArthur J, Nath A. 2007. Molecular programming of endothelin-1 in HIVinfected brain: Role of Tat in up-regulation of ET-1 and its inhibition by statins. FASEB J 21:777-789.
32. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB. 1986. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47:381-389.
33. Chen RE, Thorner J. 2007. Function and regulation in MAPK signaling pathways: Lessons learned from the yeast Saccharomyces cerevisiae. Biochim Biophys Acta 1773:1311-1340.
34. Cherner M, Masliah E, Ellis RJ, Marcotte TD, Moore DJ, Grant I, Heaton RK. 2002. Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology 59:1563-1567.
35. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB. 2000. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28:655-660.
36. Choudhuri S, Cherrington NJ, Li N, Klaassen CD. 2003. Constitutive expression of various xenobiotic and endobiotic transporter mRNAs in the choroid plexus of rats. Drug Metab Dispos 31:1337-1345.
37. Cisternino S, Mercier C, Bourasset F, Roux F, Scherrmann JM. 2004. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res 64:3296-3301.
38. Cobb MH, Goldsmith EJ. 1995. How MAP kinases are regulated. J Biol Chem 270:14843-14846.
39. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG. 1992. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654.
40. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. 1997. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 185:621-628.
41. Cosenza MA, Zhao ML, Si Q, Lee SC. 2002. Human brain parenchymal microglia express CD14 and CD45 and are productively infected by HIV-1 in HIV-1 encephalitis. Brain Pathol 12:442-455.
42. Corasaniti MT, Amantea D, Russo R, Piccirilli S, Leta A, Corazzari M, Nappi G, Bagetta G. 2005. 17beta-estradiol reduces neuronal apoptosis induced by HIV-1 gp120 in the neocortex of rat. Neurotoxicology 26:893-903.
43. Cysique LA, Maruff P, Brew BJ. 2004. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/ acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: A combined study of two cohorts. J Neurovirol 10:350-357.
44. Cysique LA, Maruff P, Brew BJ. 2006. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology 66:1447-1450.
45. Dallas S, Miller DS, Bendayan R. 2006. Multidrug resistance-associated proteins: Expression and function in the central nervous system. Pharmacol Rev 58:140-161.
46. Dallas S, Ronaldson PT, Bendayan M, Bendayan R. 2004a. Multidrug resistance protein 1-mediated transport of saquinavir by microglia. Neuroreport 15:1183-1186.
47. Dallas S, Schlichter L, Bendayan R. 2004b. Multidrug resistance protein (MRP) 4- and MRP 5-mediated efflux of 9-(2-phosphonylmethoxyethyl) adenine by microglia. J Pharmacol Exp Ther 309:1221-1229.
48. Dallas S, Zhu X, Baruchel S, Schlichter L, Bendayan R. 2003. Functional expression of the multidrug resistance protein 1 in microglia. J Pharmacol Exp Ther 307:282-290.
49. Dallasta LM, Pisarov LA, Esplen JE, Werley JV, Moses AV, Nelson JA, Achim CL. 1999. Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis. Am J Pathol 155: 1915-1927.
50. Davis LE, Hjelle BL, Miller VE, Palmer DL, Llewellyn AL, Merlin TL, Young SA, Mills RG, Wachsman W, Wiley CA. 1992. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 42:1736-1739. \ De Noronha CM, Sherman MP, Lin HW, Cavrois MV, Moir RD, Goldman RD, Greene WC. 2001. Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr. Science 294:1105-1108.
51. Decleves X, Fajac A, Lehmann-Che J, Tardy M, Mercier C, Hurbain I, Laplanche JL, Bernaudin JF, Scherrmann JM. 2002. Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines. Int J Cancer 98:173-180.
52. Decleves X, Regina A, Laplanche JL, Roux F, Boval B, Launay JM, Scherrmann JM. 2000. Functional expression of P-glycoprotein and multidrug resistance-associated protein (Mrp1) in primary cultures of rat astrocytes. J Neurosci Res 60:594-601.
53. Del-Rio Hortega P. 1932.Microglia. In: PenfieldW, editor. Cytology and cellular pathology of the nervous system. New York: Hoecher. pp 481-584.
54. Demeule M, Labelle M, Regina A, Berthelet F, Beliveau R. 2001. Isolation of endothelial cells from brain, lung, and kidney: Expression of the multidrug resistance P-glycoprotein isoforms. Biochem Biophys Res Commun 281:827-834.
55. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666.
56. Deshpande M, Zheng J, Borgmann K, Persidsky R, Wu L, Schellpeper C, Ghorpade A. 2005. Role of activated astrocytes in neuronal damage: Potential links to HIV-1-associated dementia. Neurotox Res 7:183-192.
57. Didier N, Banks WA, Creminon C, Dereuddre-Bosquet N, Mabondzo A. 2002. HIV-1-induced production of endothelin-1 in an in vitro model of the human blood-brain barrier. Neuroreport 13:1179-1183.
58. Dirson G, Fernandez C, Hindlet P, Roux F, German-Fattal M, Gimenez F, Farinotti R. 2006. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier. Pharm Res 23:1525-1532.
59. Dixit SG, Zingarelli B, Buckley DJ, Buckley AR, Pauletti GM. 2005. Nitric oxide mediates increased P-glycoprotein activity in interferon-{g}-stimulated human intestinal cells. Am J Physiol Gastrointest Liver Physiol 288:G533-G540.
60. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD. 2007. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: Implications for predicting clinical drug interactions. Drug Metab Dispos 35:1853-1859.
61. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. 1998. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665-15670.
62. Dreuw A, Hermanns HM, Heise R, Joussen S, Rodriguez F, Marquardt Y, Jugert F, Merk HF, Heinrich PC, Baron JM. 2005. Interleukin-6-type cytokines upregulate expression of multidrug resistance-associated proteins in NHEK and dermal fibroblasts. J Invest Dermatol 124:28-37.
63. Dreyer EB, Kaiser PK, Offermann JT, Lipton SA. 1990. HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists. Science 248:364-367.
64. Duret C, Daujat-Chavanieu M, Pascussi JM, Pichard-Garcia L, Balaguer P, Fabre JM, Vilarem MJ, Maurel P, Gerbal-Chaloin S. 2006. Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: Consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor. Mol Pharmacol 70:329-339.
65. Dussault I, Lin M, Hollister K, Wang EH, Synold TW, Forman BM. 2001. Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J Biol Chem 276:33309-33312.
66. Eisenblatter T, Huwel S, Galla HJ. 2003. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier. Brain Res 971:221-231.
67. Farnet CM, Haseltine WA. 1991. Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex. J Virol 65:1910-1915.
68. Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, Saag MS, Goebel FD, Rockstroh JK, Dezube BJ, Jenkins TM, Medhurst C, Sullivan JF, Ridgway C, Abel S, James IT, Youle M, van der RE. 2005. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 11:1170-1172.
69. Faucette SR, Zhang TC, Moore R, Sueyoshi T, Omiecinski CJ, LeCluyse EL, Negishi M, Wang H. 2007. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 320:72-80.
70. Felix RA, Barrand MA. 2002. P-glycoprotein expression in rat brain endothelial cells: evidence for regulation by transient oxidative stress. J Neurochem 80:64-72.
71. Feng Y, Broder CC, Kennedy PE, Berger EA. 1996. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G proteincoupled receptor. Science 272:872-877.
72. Fischer-Smith T, Rappaport J. 2005. Evolving paradigms in the pathogenesis of HIV-1-associated dementia. Expert Rev Mol Med 7:1-26.
73. Freed EO. 2001. HIV-1 replication. Somat Cell Mol Genet 26:13-33.
74. Furler MD, Einarson TR, Walmsley S, Millson M, Bendayan R. 2004. Polypharmacy in HIV: Impact of data source and gender on reported drug utilization. AIDS Patient Care STDS 18:568-586.
75. Gabuzda D, Wang J. 2000. Chemokine receptors and mechanisms of cell death in HIV neuropathogenesis. J Neurovirol 6 (Suppl 1):S24-S32.
76. Gelbard HA, Nottet HS, Swindells S, Jett M, Dzenko KA, Genis P, White R, Wang L, Choi YB, Zhang D. 1994. Platelet-activating factor: A candidate human immunodeficiency virus type 1-induced neurotoxin. J Virol 68:4628-4635.
77. Gendelman HE. 2002. Neural immunity: Friend or foe? J Neurovirol 8:474-479.
78. Gendelman HE, Orenstein JM, Martin MA, Ferrua C, Mitra R, Phipps T, Wahl LA, Lane HC, Fauci AS, Burke DS. 1988. Efficient isolation and propagation of human immunodeficiency virus on recombinant colonystimulating factor 1-treated monocytes. J Exp Med 167:1428-1441.
79. Gerlach JH, Endicott JA, Juranka PF, Henderson G, Sarangi F, Deuchars KL, Ling V. 1986. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature 324:485-489.
80. Ghafouri M, Amini S, Khalili K, Sawaya BE. 2006. HIV-1 associated dementia: Symptoms and causes. Retrovirology 3:28.
81. Ghorpade A, Holter S, Borgmann K, Persidsky R, Wu L. 2003. HIV-1 and IL-1 b regulate Fas ligand expression in human astrocytes through the NF-jB pathway. J Neuroimmunol 141:141-149.
82. Giulian D, Vaca K, Noonan CA. 1990. Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1. Science 250:1593-1596.
83. Giulian D, Wendt E, Vaca K, Noonan CA. 1993. The envelope glycoprotein of human immunodeficiency virus type 1 stimulates release of neurotoxins from monocytes. Proc Natl Acad Sci USA 90:2769-2773.
84. Giulian D, Yu J, Li X, Tom D, Li J, Wendt E, Lin SN, Schwarcz R, Noonan C. 1996. Study of receptor-mediated neurotoxins released by HIV-1-infected mononuclear phagocytes found in human brain. J Neurosci 16:3139-3153.
85. Glass JD, Fedor H, Wesselingh SL, McArthur JC. 1995. Immunocytochemical quantitation of human immunodeficiency virus in the brain: Correlations with dementia. Ann Neurol 38:755-762.
86. Golden PL, Pardridge WM. 1999. P-Glycoprotein on astrocyte foot processes of unfixed isolated human brain capillaries. Brain Res 819:143- 146.
87. Goralski KB, Hartmann G, Piquette-Miller M, Renton KW. 2003. Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin. Br J Pharmacol 139:35-48.
88. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I. 1995. Genetic analysis of the multidrug transporter. Annu Rev Genet 29:607-649.
89. Graf GA, Li WP, Gerard RD, Gelissen I, White A, Cohen JC, Hobbs HH. 2002. Coexpression of ATP-binding cassette proteins ABCG5 and ABCG8 permits their transport to the apical surface. J Clin Invest 110:659-669.
90. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD. 2007. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial. Lancet 369:1261-1269.
91. Gros P, Croop J, Housman D. 1986. Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 47:371-380.
92. Guo Y, Kotova E, Chen ZS, Lee K, Hopper-Borge E, Belinsky MG, Kruh GD. 2003. MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 20,30-dideoxycytidine and 90-(20-phosphonylmethoxyethyl)adenine. J Biol Chem 278:29509-29514.
93. Gupta A, Dai Y, Vethanayagam RR, Hebert MF, Thummel KE, Unadkat JD, Ross DD, Mao Q. 2006. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol 58:374-383.
94. Gupta A, Zhang Y, Unadkat JD, Mao Q. 2004. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther 310:334-341.
95. Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Derijard B, Davis RJ. 1996. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 15:2760-2770.
96. Gupta S, Campbell D, Derijard B, Davis RJ. 1995. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 267:389-393.
97. Gutmann H, Fricker G, Drewe J, Toeroek M, Miller DS. 1999. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 56:383-389.
98. Hallenberger S, Bosch V, Angliker H, Shaw E, Klenk HD, Garten W. 1992. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature 360:358-361.
99. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA. 2006. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296:827-843.
100. Hartmann G, Cheung AK, Piquette-Miller M. 2002. Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J Pharmacol Exp Ther 303:273-281.
101. Hartz AM, Bauer B, Fricker G, Miller DS. 2006. Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-a and lipopolysaccharide. Mol Pharmacol 69:462- 470.
102. Hayashi K, Pu H, Andras IE, Eum SY, Yamauchi A, Hennig B, Toborek M. 2006. HIV-TAT protein upregulates expression of multidrug resistance protein 1 in the blood-brain barrier. J Cereb Blood Flow Metab 26:1052-1065.
103. Hayashi K, Pu H, Tian J, Andras IE, Lee YW, Hennig B, Toborek M. 2005. HIV-Tat protein induces P-glycoprotein expression in brain microvascular endothelial cells. J Neurochem 93:1231-1241.
104. Hennessy M, Kelleher D, Spiers JP, Barry M, Kavanagh P, Back D, Mulcahy F, Feely J. 2002. St Johns wort increases expression of Pglycoprotein: Implications for drug interactions. Br J Clin Pharmacol 53:75-82.
105. Hesselgesser J, Taub D, Baskar P, Greenberg M, Hoxie J, Kolson DL, Horuk R. 1998. Neuronal apoptosis induced by HIV-1 gp120 and the chemokine SDF-1 a is mediated by the chemokine receptor CXCR4. Curr Biol 8:595-598.
106. Heyes MP, Brew BJ, Martin A, Price RW, Salazar AM, Sidtis JJ, Yergey JA, Mouradian MM, Sadler AE, Keilp J. 1991. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: Relationship to clinical and neurological status. Ann Neurol 29:202-209.
107. Higgins CF, Callaghan R, Linton KJ, Rosenberg MF, Ford RC. 1997. Structure of the multidrug resistance P-glycoprotein. Semin Cancer Biol 8:135-142.
108. Hirrlinger J, Konig J, Dringen R. 2002a. Expression of mRNAs of multidrug resistance proteins (Mrps) in cultured rat astrocytes, oligodendrocytes, microglial cells and neurones. J Neurochem 82:716- 719.
109. Hirrlinger J, Konig J, Keppler D, Lindenau J, Schulz JB, Dringen R. 2001. The multidrug resistance protein MRP1 mediates the release of glutathione disulfide from rat astrocytes during oxidative stress. J Neurochem 76:627-636.
110. Hirrlinger J, Moeller H, Kirchhoff F, Dringen R. 2005. Expression of multidrug resistance proteins (Mrps) in astrocytes of the mouse brain: A single cell RT-PCR study. Neurochem Res 30:1237-1244.
111. Hirrlinger J, Schulz JB, Dringen R. 2002b. Glutathione release from cultured brain cells: Multidrug resistance protein 1 mediates the release of GSH from rat astroglial cells. J Neurosci Res 69:318-326.
112. Hoffman TL, LaBranche CC, Zhang W, Canziani G, Robinson J, Chaiken I, Hoxie JA, Doms RW. 1999. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc Natl Acad Sci USA 96:6359-6364.
113. Holguin A, O'Connor KA, Biedenkapp J, Campisi J, Wieseler-Frank J, Milligan ED, Hansen MK, Spataro L, Maksimova E, Bravmann C, Martin D, Fleshner M, Maier SF, Watkins LR. 2004. HIV-1 gp120 stimulates proinflammatory cytokine-mediated pain facilitation via activation of nitric oxide synthase-I (nNOS). Pain 110:517- 530.
114. Hori K, Burd PR, Furuke K, Kutza J, Weih KA, Clouse KA. 1999. Human immunodeficiency virus-1-infected macrophages induce inducible nitric oxide synthase and nitric oxide (NO) production in astrocytes: Astrocytic NO as a possible mediator of neural damage in acquired immunodeficiency syndrome. Blood 93:1843-1850.
115. Hori S, Ohtsuki S, Tachikawa M, Kimura N, Kondo T, Watanabe M, Nakashima E, Terasaki T. 2004. Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte-derived soluble factor(s). J Neurochem 90:526-536.
116. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH. 2001. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 59:806-813.
117. Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. 2007. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol 71:619-627.
118. Janneh O, Jones E, Chandler B, Owen A, Khoo SH. 2007. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 60:987-993.
119. Janneh O, Owen A, Chandler B, Hartkoorn RC, Hart CA, Bray PG, Ward SA, Back DJ, Khoo SH. 2005. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS 19:2097-2102.
120. Janzer RC, Raff MC. 1987. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature 325:253-257.
121. Jedlitschky G, Burchell B, Keppler D. 2000. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 275:30069-30074.
122. Jodoin J, Demeule M, Fenart L, Cecchelli R, Farmer S, Linton KJ, Higgins CF, Beliveau R. 2003. P-glycoprotein in blood-brain barrier endothelial cells: Interaction and oligomerization with caveolins. J Neurochem 87:1010-1023.
123. Jones K, Bray PG, Khoo SH, Davey RA, Meaden ER, Ward SA, Back DJ. 2001. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: Potential for accelerated viral drug resistance? AIDS 15:1353-1358.
124. Juliano RL, Ling V. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162.
125. Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, Tontonoz P, Kliewer S, Willson TM, Edwards PA. 2002. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 277:2908-2915.
126. Kaul M, Zheng J, Okamoto S, Gendelman HE, Lipton SA. 2005. HIV-1 infection and AIDS: Consequences for the central nervous system. Cell Death Differ 12 (Suppl 1):878-892.
127. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR. 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289-294.
128. Koenig S, Gendelman HE, Orenstein JM, Dal Canto MC, Pezeshkpour GH, Yungbluth M, Janotta F, Aksamit A, Martin MA, Fauci AS. 1986. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233:1089-1093.
129. Kohler JJ, Tuttle DL, Coberley CR, Sleasman JW, Goodenow MM. 2003. Human immunodeficiency virus type 1 (HIV-1) induces activation of multiple STATs in CD41 cells of lymphocyte or monocyte/macrophage lineages. J Leukoc Biol 73:407-416.
130. Kolchinsky P, Kiprilov E, Sodroski J. 2001. Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J Virol 75:2041-2050.
131. Koller H, Schaal H, Rosenbaum C, Czardybon M, Von Giesen HJ, Muller HW, Arendt G. 2002. Functional CXCR4 receptor development parallels sensitivity to HIV-1 gp120 in cultured rat astroglial cells but not in cultured rat cortical neurons. J Neurovirol 8:411-419.
132. Kong LY, Wilson BC, McMillian MK, Bing G, Hudson PM, Hong JS. 1996. The effects of the HIV-1 envelope protein gp120 on the production of nitric oxide and proinflammatory cytokines in mixed glial cell cultures. Cell Immunol 172:77-83.
133. Koyama Y, Tsujikawa K, Matsuda T, Baba A. 2003. Endothelin-1 stimulates glial cell line-derived neurotrophic factor expression in cultured rat astrocytes. Biochem Biophys Res Commun 303:1101-1105.
134. Langford D, Grigorian A, Hurford R, Adame A, Ellis RJ, Hansen L, Masliah E. 2004. Altered P-glycoprotein expression in AIDS patients with HIV encephalitis. J Neuropathol Exp Neurol 63:1038-1047.
135. Langford D, Marquie-Beck J, de Almeida S, Lazzaretto D, Letendre S, Grant I, McCutchan JA, Masliah E, Ellis RJ. 2006. Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. J Neurovirol 12:100-107.
136. Langford TD, Letendre SL, Larrea GJ, Masliah E. 2003. Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathol 13:195-210.
137. Lazarowski AJ, Lubieniecki FJ, Camarero SA, Pomata HH, Bartuluchi MA, Sevlever G, Taratuto AL. 2006. New proteins configure a brain drug resistance map in tuberous sclerosis. Pediatr Neurol 34:20-24.
138. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, Dey S. 1998. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37:3594-3601.
139. Lee G, Babakhanian K, Ramaswamy M, Prat A, Wosik K, Bendayan R. 2007. Expression of the ATP-binding cassette membrane transporter, ABCG2, in human and rodent brain microvessel endothelial and glial cell culture systems. Pharm Res 24:1262-1274.
140. Lee G, Dallas S, Hong M, Bendayan R. 2001a. Drug transporters in the central nervous system: Brain barriers and brain parenchyma considerations. Pharmacol Rev 53:569-596.
141. Lee G, Schlichter L, Bendayan M, Bendayan R. 2001b. Functional expression of P-glycoprotein in rat brain microglia. J Pharmacol Exp Ther 299:204-212.
142. Lee YJ, Kusuhara H, Jonker JW, Schinkel AH, Sugiyama Y. 2005. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: A minor role of breast cancer resistance protein. J Pharmacol Exp Ther 312:44-52.
143. Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, Mercer KE, Zhuang Y, Panetta JC, Johnston B, Scheper RJ, Stewart CF, Schuetz JD. 2004. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 24:7612-7621.
144. Leslie EM, Deeley RG, Cole SP. 2005. Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216-237.
145. Levy DE, Lee CK. 2002. What does Stat3 do? J Clin Invest 109:1143- 1148.
146. Liu NQ, Lossinsky AS, Popik W, Li X, Gujuluva C, Kriederman B, Roberts J, Pushkarsky T, Bukrinsky M, Witte M, Weinand M, Fiala M. 2002a. Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen-activated protein kinase signaling pathway. J Virol 76:6689-6700.
147. Liu X, Jana M, Dasgupta S, Koka S, He J, Wood C, Pahan K. 2002b. Human immunodeficiency virus type 1 (HIV-1) tat induces nitric-oxide synthase in human astroglia. J Biol Chem 277:39312-39319.
148. Liu Y, Liu H, Kim BO, Gattone VH, Li J, Nath A, Blum J, He JJ. 2004. CD4-independent infection of astrocytes by human immunodeficiency virus type 1: Requirement for the human mannose receptor. J Virol 78:4120-4133.
149. Liu Y, Tang XP, McArthur JC, Scott J, Gartner S. 2000. Analysis of human immunodeficiency virus type 1 gp160 sequences from a patient with HIV dementia: Evidence for monocyte trafficking into brain. J Neurovirol 6 (Suppl 1):S70-S81.
150. Loo TW, Clarke DM. 2005. Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J Membr Biol 206:173- 185.
151. Loscher W, Potschka H. 2005. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2:86-98.
152. Maher J, Choudhri S, Halliday W, Power C, Nath A. 1997. AIDS dementia complex with generalized myoclonus. Mov Disord 12:593-597.
153. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, Schellens JH. 2001. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464.
154. Malorni W, Lucia MB, Rainaldi G, Cauda R, Cianfriglia M, Donelli G, Ortona L. 1998. Intracellular expression of P-170 glycoprotein in peripheral blood mononuclear cell subsets from healthy donors and HIV-infected patients. Haematologica 83:13-20.
155. Martin J, LaBranche CC, Gonzalez-Scarano F. 2001. Differential CD4/ CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate. J Virol 75:3568-3580.
156. Masliah E, Heaton RK, Marcotte TD, Ellis RJ, Wiley CA, Mallory M, Achim CL, McCutchan JA, Nelson JA, Atkinson JH, Grant I. 1997. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol 42:963-972.
157. Matheny CJ, Ali RY, Yang X, Pollack GM. 2004. Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues. Drug Metab Dispos 32:1008-1014.
158. Mayne M, Bratanich AC, Chen P, Rana F, Nath A, Power C. 1998. HIV-1 tat molecular diversity and induction of TNF-a: Implications for HIVinduced neurological disease. Neuroimmunomodulation 5:184-192.
159. McArthur JC, Haughey N, Gartner S, Conant K, Pardo C, Nath A, Sacktor N. 2003. Human immunodeficiency virus-associated dementia: An evolving disease. J Neurovirol 9:205-221.
160. McDonald D, Vodicka MA, Lucero G, Svitkina TM, Borisy GG, Emerman M, Hope TJ. 2002. Visualization of the intracellular behavior of HIV in living cells. J Cell Biol 159:441-452.
161. McGee B, Smith N, Aweeka F. 2006. HIV pharmacology: Barriers to the eradication of HIV from the CNS. HIV Clin Trials 7:142-153.
162. Meissner K, Jedlitschky G, Meyer zu SH, Dazert P, Eckel L, Vogelgesang S, Warzok RW, Bohm M, Lehmann C, Wendt M, Cascorbi I, Kroemer HK. 2004. Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacogenetics 14:381-385.
163. Merino G, Alvarez AI, Pulido MM, Molina AJ, Schinkel AH, Prieto JG. 2006. Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos 34:690-695.
164. Miao ZH, Ding J. 2003. Transcription factor c-Jun activation represses mdr-1 gene expression. Cancer Res 63:4527-4532.
165. Miller DS, Nobmann SN, Gutmann H, Toeroek M, Drewe J, Fricker G. 2000. Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol Pharmacol 58:1357-1367.
166. Minich T, Riemer J, Schulz JB, Wielinga P, Wijnholds J, Dringen R. 2006. The multidrug resistance protein 1 (Mrp1), but not Mrp5, mediates export of glutathione and glutathione disulfide from brain astrocytes. J Neurochem 97:373-384.
167. Mirsattari SM, Berry ME, Holden JK, Ni W, Nath A, Power C. 1999. Paroxysmal dyskinesias in patients with HIV infection. Neurology 52:109-114.
168. Nath A, Conant K, Chen P, Scott C, Major EO. 1999. Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon. J Biol Chem 274:17098-17102.
169. Navia BA, Jordan BD, Price RW. 1986. The AIDS dementia complex. I. Clinical features. Ann Neurol 19:517-524.
170. Nermut MV, Fassati A. 2003. Structural analyses of purified human immunodeficiency virus type 1 intracellular reverse transcription complexes. J Virol 77:8196-8206.
171. New DR, Ma M, Epstein LG, Nath A, Gelbard HA. 1997. Human immunodeficiency virus type 1 Tat protein induces death by apoptosis in primary human neuron cultures. J Neurovirol 3:168-173.
172. Nichols WG, Steel HM, Bonny T, Adkison K, Curtis L, Millard J, Kabeya K, Clumeck N. 2008. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother 52:858- 865.
173. Nies AT, Jedlitschky G, Konig J, Herold-Mende C, Steiner HH, Schmitt HP, Keppler D. 2004. Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 129:349-360.
174. Nottet HS, Gendelman HE. 1995. Unraveling the neuroimmune mechanisms for the HIV-1-associated cognitive/motor complex. Immunol Today 16:441-448.
175. Nottet HS, Persidsky Y, Sasseville VG, Nukuna AN, Bock P, Zhai QH, Sharer LR, McComb RD, Swindells S, Soderland C, Gendelman HE. 1996. Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. J Immunol 156:1284-1295.
176. Oldfield V, Plosker GL. 2006. Lopinavir/ritonavir: A review of its use in the management of HIV infection. Drugs 66:1275-1299.
177. Pardridge WM, Golden PL, Kang YS, Bickel U. 1997. Brain microvascular and astrocyte localization of P-glycoprotein. J Neurochem 68:1278-1285.
178. Park S, Sinko PJ. 2005. P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. J Pharmacol Exp Ther 312:1249-1256.
179. Perloff ES, Duan SX, Skolnik PR, Greenblatt DJ, Von Moltke LL. 2005. Atazanavir: Effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos 33:764-770.
180. Perloff MD, Stormer E, Von Moltke LL, Greenblatt DJ. 2003. Rapid assessment of P-glycoprotein inhibition and induction in vitro. Pharm Res 20:1177-1183.
181. Perloff MD, Von Moltke LL, Greenblatt DJ. 2002. Fexofenadine transport in Caco-2 cells: Inhibition with verapamil and ritonavir. J Clin Pharmacol 42:1269-1274.
182. Perloff MD, Von Moltke LL, Marchand JE, Greenblatt DJ. 2001a. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J Pharm Sci 90:1829- 1837.
183. Perloff MD, Von Moltke LL, Stormer E, Shader RI, Greenblatt DJ. 2001b. Saint John's wort: An in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol 134:1601-1608.
184. Perry CM, Frampton JE, McCormack PL, Siddiqui MA, Cvetkovic RS. 2005. Nelfinavir: A review of its use in the management of HIV infection. Drugs 65:2209-2244.
185. Persidsky Y, Gendelman HE. 2003. Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection. J Leukoc Biol 74:691-701.
186. Persidsky Y, Ghorpade A, Rasmussen J, Limoges J, Liu XJ, Stins M, Fiala M, Way D, Kim KS, Witte MH, Weinand M, Carhart L, Gendelman HE. 1999. Microglial and astrocyte chemokines regulate monocyte migration through the blood-brain barrier in human immunodeficiency virus-1 encephalitis. Am J Pathol 155:1599-1611.
187. Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. 2006. Blood-brain barrier: Structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 1:223-236.
188. Pfeiffer SE, Warrington AE, Bansal R. 1993. The oligodendrocyte and its many cellular processes. Trends Cell Biol 3:191-197.
189. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. 2000. Indinavir concentrations and St John's wort. Lancet 355:547-548.
190. Polgar O, Robey RW, Bates SE. 2008. ABCG2: Structure, function and role in drug response. Expert Opin Drug Metab Toxicol 4:1-15.
191. Price TO, Ercal N, Nakaoke R, Banks WA. 2005. HIV-1 viral proteins gp120 and Tat induce oxidative stress in brain endothelial cells. Brain Res 1045:57-63.
192. Pu H, Tian J, Flora G, Lee YW, Nath A, Hennig B, Toborek M. 2003. HIV-1 Tat protein upregulates inflammatory mediators and induces monocyte invasion into the brain. Mol Cell Neurosci 24:224-237.
193. Raivich G, Bohatschek M, Kloss CU, Werner A, Jones LL, Kreutzberg GW. 1999. Neuroglial activation repertoire in the injured brain: Graded response, molecular mechanisms and cues to physiological function. Brain Res Brain Res Rev 30:77-105.
194. Ranki A, Nyberg M, Ovod V, Haltia M, Elovaara I, Raininko R, Haapasalo H, Krohn K. 1995. Abundant expression of HIV Nef and Rev proteins in brain astrocytes in vivo is associated with dementia. AIDS 9:1001-1008.
195. Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, Piwnica-Worms D. 1999. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci USA 96:3900-3905.
196. Reid G, Wielinga P, Zelcer N, de Haas M, Van Deemter L, Wijnholds J, Balzarini J, Borst P. 2003. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol 63:1094-1103.
197. Rius M, Hummel-Eisenbeiss J, Hofmann AF, Keppler D. 2006. Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione. Am J Physiol Gastrointest Liver Physiol 290:G640-G649.
198. Rivest S. 2003. Molecular insights on the cerebral innate immune system. Brain Behav Immun 17:13-19.
199. Robey RW, Steadman K, Polgar O, Bates SE. 2005. ABCG2-mediated transport of photosensitizers: Potential impact on photodynamic therapy. Cancer Biol Ther 4:187-194.
200. Ronaldson PT, Babakhanian K, Bendayan R. 2007a. Drug transport in the brain. In: You G, Morris ME, editors. Drug transporters: Molecular characterization and role in drug disposition. Hoboken: Wiley. pp 411-461.
201. Ronaldson PT, Bendayan M, Gingras D, Piquette-Miller M, Bendayan R. 2004a. Cellular localization and functional expression of P-glycoprotein in rat astrocyte cultures. J Neurochem 89:788-800.
202. Ronaldson PT, Bendayan R. 2006. HIV-1 viral envelope glycoprotein gp120 triggers an inflammatory response in cultured rat astrocytes and regulates the functional expression of P-glycoprotein. Mol Pharmacol 70:1087-1098.
203. Ronaldson PT, Bendayan R. 2008. HIV-1 viral envelope glycoprotein gp120 produces oxidative stress and regulates the functional expression of multidrug resistance protein-1 (Mrp1) in glial cells. J Neurochem [Epub ahead of print].
204. Ronaldson PT, Chan J, Bendayan R. 2007b. Involvement of the MAPK pathway in the regulation of P-glycoprotein (P-gp) expression in cultured glial cells triggered with HIV-1 envelope protein gp120. Abstract #T3456. Paper Presented at the American Association of Pharmaceutical Scientists' Annual Meeting and Exposition, San Diego CA, November 11-15, 2007.
205. Ronaldson PT, Lee G, Dallas S, Bendayan R. 2004b. Involvement of Pglycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines. Pharm Res 21:811- 818.
206. Ronaldson PT, Tran CS, Rasaiah VPA, Bendayan R. 2007c. Increased functional expression of multidrug resistance protein 1 (Mrp1) in cultured glial cells treated with the HIV-1 viral envelope protein gp120 and cytokines. Abstract #O003. Can J Infect Dis 18:13B.
207. Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L. 2002. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 8:136-142.
208. Sanchez-Ramon S, Bellon JM, Resino S, Canto-Nogues C, Gurbindo D, Ramos JT, Munoz-Fernandez MA. 2003. Low blood CD81 T-lymphocytes and high circulating monocytes are predictors of HIV-1-associated progressive encephalopathy in children. Pediatrics 111:E168-E175.
209. Schinkel AH, Kemp S, Dolle M, Rudenko G, Wagenaar E. 1993. N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein. J Biol Chem 268:7474-7481.
210. Schlachetzki F, Pardridge WM. 2003. P-glycoprotein and caveolin-1a in endothelium and astrocytes of primate brain. Neuroreport 14:2041- 2046.
211. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A, Fridland A. 1999. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 5:1048- 1051.
212. Shaik N, Giri N, Pan G, Elmquist WF. 2007. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metab Dispos 35:2076- 2085.
213. Sharom FJ. 2006. Shedding light on drug transport: Structure and function of the P-glycoprotein multidrug transporter (ABCB1). Biochem Cell Biol 84:979-992.
214. Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, Allaway GP, Martin DE. 2007. Phase I, II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(30,30-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother 51:3574-3581.
215. Spagnolo A, Grant EN, Glick R, Lichtor T, Feinstein DL. 2007. Differential effects of PPARg agonists on the metabolic properties of gliomas and astrocytes. Neurosci Lett 417:72-77.
216. Speth C, Dierich MP, Sopper S. 2005. HIV-infection of the central nervous system: The tightrope walk of innate immunity. Mol Immunol 42:213-228.
217. Spiegl-Kreinecker S, Buchroithner J, Elbling L, Steiner E, Wurm G, Bodenteich A, Fischer J, Micksche M, Berger W. 2002. Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes. J Neurooncol 57:27-36.
218. Srinivas RV, Middlemas D, Flynn P, Fridland A. 1998. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother 42:3157-3162.
219. Stins MF, Pearce D, Di Cello F, Erdreich-Epstein A, Pardo CA, Sik KK. 2003. Induction of intercellular adhesion molecule-1 on human brain endothelial cells by HIV-1 gp120: Role of CD4 and chemokine coreceptors. Lab Invest 83:1787-1798.
220. Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. 2007. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 73:1573-1581.
221. Sui Z, Sniderhan LF, Schifitto G, Phipps RP, Gelbard HA, Dewhurst S, Maggirwar SB. 2007. Functional synergy between CD40 ligand and HIV-1 Tat contributes to inflammation: Implications in HIV type 1 dementia. J Immunol 178:3226-3236.
222. Sukhai M, Yong A, Pak A, Piquette-Miller M. 2001. Decreased expression of P-glycoprotein in interleukin-1 beta and interleukin-6 treated rat hepatocytes. Inflamm Res 50:362-370.
223. Swainston HT, Scott LJ. 2005. Atazanavir: A review of its use in the management of HIV infection. Drugs 65:2309-2336.
224. Szatmari I, Vamosi G, Brazda P, Balint BL, Benko S, Szeles L, Jeney V, Ozvegy-Laczka C, Szanto A, Barta E, Balla J, Sarkadi B, Nagy L. 2006. Peroxisome proliferator-activated receptor g-regulated ABCG2 expression confers cytoprotection to human dendritic cells. J Biol Chem 281:23812-23823.
225. Temesgen Z, Warnke D, Kasten MJ. 2006. Current status of antiretroviral therapy. Expert Opin Pharmacother 7:1541-1554.
226. Teng S, Jekerle V, Piquette-Miller M. 2003. Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab Dispos 31:1296-1299.
227. Teng S, Piquette-Miller M. 2005. The involvement of the pregnane X receptor in hepatic gene regulation during inflammation in mice. J Pharmacol Exp Ther 312:841-848.
228. Thibault S, Tardif MR, Barat C, Tremblay MJ. 2007. TLR2 signaling renders quiescent naive and memory CD41 T cells more susceptible to productive infection with X4 and R5 HIV-type 1. J Immunol 179:4357-4366.
229. Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC, Nguyen QH, Nguyen TT, Nguyen NH, Nguyen TN, Nguyen NL, Nguyen HD, Vu NT, Cao HH, Tran TH, Pham PM, Nguyen TD, Stepniewska K, White NJ, Tran TH, Farrar JJ. 2004. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 351:1741-1751.
230. Toborek M, Lee YW, Pu H, Malecki A, Flora G, Garrido R, Hennig B, Bauer HC, Nath A. 2003. HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium. J Neurochem 84:169-179.
231. Tong L, Phan TK, Robinson KL, Babusis D, Strab R, Bhoopathy S, Hidalgo IJ, Rhodes GR, Ray AS. 2007. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother 51:3498-3504.
232. Tornatore C, Chandra R, Berger JR, Major EO. 1994. HIV-1 infection of subcortical astrocytes in the pediatric central nervous system. Neurology 44:481-487.
233. Tornatore C, Nath A, Amemiya K, Major EO. 1991. Persistent human immunodeficiency virus type 1 infection in human fetal glial cells reactivated by T-cell factor(s) or by the cytokines tumor necrosis factor a and interleukin-1 b. J Virol 65:6094-6100.
234. Treisman R. 1996. Regulation of transcription by MAP kinase cascades. Curr Opin Cell Biol 8:205-215.
235. Trillo-Pazos G, Diamanturos A, Rislove L, Menza T, Chao W, Belem P, Sadiq S, Morgello S, Sharer L, Volsky DJ. 2003. Detection of HIV-1 DNA in microglia/macrophages, astrocytes and neurons isolated from brain tissue with HIV-1 encephalitis by laser capture microdissection. Brain Pathol 13:144-154.
236. UNAIDS. 2006. 2006 report on the global AIDS epidemic: A UNAIDS 10th anniversary special edition. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS) andWorld Health Organization (WHO).
237. Urquhart BL, Tirona RG, Kim RB. 2007. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: Implications for interindividual variability in response to drugs. J Clin Pharmacol 47:566-578.
238. Valcour V, Shikuma C, Shiramizu B, Watters M, Poff P, Selnes O, Holck P, Grove J, Sacktor N. 2004. Higher frequency of dementia in older HIV-1 individuals: The Hawaii Aging with HIV-1 Cohort. Neurology 63:822-827.
239. Valentin A, Trivedi H, Lu W, Kostrikis LG, Pavlakis GN. 2000. CXCR4 mediates entry and productive infection of syncytia-inducing (X4) HIV-1 strains in primary macrophages. Virology 269:294-304.
240. Verani A, Gras G, Pancino G. 2005. Macrophages and HIV-1: Dangerous liaisons. Mol Immunol 42:195-212.
241. Verani A, Pesenti E, Polo S, Tresoldi E, Scarlatti G, Lusso P, Siccardi AG, Vercelli D. 1998. CXCR4 is a functional coreceptor for infection of human macrophages by CXCR4-dependent primary HIV-1 isolates. J Immunol 161:2084-2088.
242. Virgintino D, Errede M, Girolamo F, Capobianco C, Robertson D, Vimercati A, Serio G, Di Benedetto A, Yonekawa Y, Frei K, Roncali L. 2008. Fetal blood-brain barrier P-glycoprotein contributes to brain protection during human development. J Neuropathol Exp Neurol 67:50-61.
243. Virgintino D, Robertson D, Errede M, Benagiano V, Girolamo F, Maiorano E, Roncali L, Bertossi M. 2002. Expression of P-glycoprotein in human cerebral cortex microvessels. J Histochem Cytochem 50:1671-1676.
244. Visalli V, Muscoli C, Sacco I, Sculco F, Palma E, Costa N, Colica C, Rotiroti D, Mollace V. 2007. N-acetylcysteine prevents HIV gp 120-related damage of human cultured astrocytes: Correlation with glutamine synthase dysfunction. BMC Neurosci 8:106.
245. Volk H, Potschka H, Loscher W. 2005. Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fixation and staining variables. J Histochem Cytochem 53:517-531.
246. Volterra A, Meldolesi J. 2005. Astrocytes, from brain glue to communication elements: The revolution continues. Nat Rev Neurosci 6:626-640.
247. Walmsley S. 2007. Protease inhibitor-based regimens for HIV therapy: Safety and efficacy. J Acquir Immune Defic Syndr 45 (Suppl 1):S5- S13.
248. Walsh KA, Megyesi JF, Wilson JX, Crukley J, Laubach VE, Hammond RR. 2004. Antioxidant protection from HIV-1 gp120-induced neuroglial toxicity. J Neuroinflammation 1:8.
249. Walz W. 2000. Controversy surrounding the existence of discrete functional classes of astrocytes in adult gray matter. Glia 31:95-103.
250. Wang X, Baba M. 2005. The role of breast cancer resistance protein (BCRP/ABCG2) in cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Antivir Chem Chemother 16:213-216.
251. Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S, Baba M. 2003. Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol 63:65-72.
252. Wang XZ, Ron D. 1996. Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD153) by p38 MAP Kinase. Science 272:1347-1349.
253. Wang Z, Pekarskaya O, Bencheikh M, Chao W, Gelbard HA, Ghorpade A, Rothstein JD, Volsky DJ. 2003. Reduced expression of glutamate transporter EAAT2 and impaired glutamate transport in human primary astrocytes exposed to HIV-1 or gp120. Virology 312:60-73.
254. Washington CB, Wiltshire HR, Man M, Moy T, Harris SR, Worth E, Weigl P, Liang Z, Hall D, Marriott L, Blaschke TF. 2000. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. Drug Metab Dispos 28:1058-1062.
255. Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, Haefeli WE, Efferth T. 2007a. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 59:238-245.
256. Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli WE. 2007b. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors Drug Metab Dispos 35:340-344.
257. Weiss J, Weis N, Ketabi-Kiyanvash N, Storch CH, Haefeli WE. 2008. Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors. Eur J Pharmacol 579:104-109.
258. Wijnholds J, Mol CA, Van Deemter L, de Haas M, Scheffer GL, Baas F, Beijnen JH, Scheper RJ, Hatse S, De Clercq E, Balzarini J, Borst P. 2000. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA 97:7476-7481.
259. Williams GC, Liu A, Knipp G, Sinko PJ. 2002. Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother 46:3456-3462.
260. Williams KC, Corey S, Westmoreland SV, Pauley D, Knight H, deBakker C, Alvarez X, Lackner AA. 2001. Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: Implications for the neuropathogenesis of AIDS. J Exp Med 193:905-915.
261. Wilson R, Brophy PJ. 1989. Role for the oligodendrocyte cytoskeleton in myelination. J Neurosci Res 22:439-448.
262. Woster AP, Combs CK. 2007. Differential ability of a thiazolidinedione PPARg agonist to attenuate cytokine secretion in primary microglia and macrophage-like cells. J Neurochem 103:67-76.
263. Wu L, LaRosa G, Kassam N, Gordon CJ, Heath H, Ruffing N, Chen H, Humblias J, Samson M, Parmentier M, Moore JP, Mackay CR. 1997. Interaction of chemokine receptor CCR5 with its ligands: Multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med 186:1373-1381.
264. Wyatt R, Sodroski J. 1998. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science 280:1884-1888.
265. Wynn HE, Brundage RC, Fletcher CV. 2002. Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs 16:595-609.
266. Xiong H, Yoshinari K, Brouwer KL, Negishi M. 2002. Role of constitutive androstane receptor in the in vivo induction of Mrp3 and CYP2B1/2 by phenobarbital. Drug Metab Dispos 30:918-923.
267. Xiong H, Zeng YC, Lewis T, Zheng J, Persidsky Y, Gendelman HE. 2000. HIV-1 infected mononuclear phagocyte secretory products affect neuronal physiology leading to cellular demise: Relevance for HIV-1-associated dementia. J Neurovirol 6 (Suppl 1):S14-S23.
268. Yabuuchi H, Takayanagi S, Yoshinaga K, Taniguchi N, Aburatani H, Ishikawa T. 2002. ABCC13, an unusual truncated ABC transporter, is highly expressed in fetal human liver. Biochem Biophys Res Commun 299:410-417.
269. Yeung MC, Pulliam L, Lau AS. 1995. The HIV envelope protein gp120 is toxic to human brain-cell cultures through the induction of interleukin-6 and tumor necrosis factor-a. AIDS 9:137-143.
270. Yi Y, Rana S, Turner JD, Gaddis N, Collman RG. 1998. CXCR-4 is expressed by primary macrophages and supports CCR5-independent infection by dual-tropic but not T-tropic isolates of human immunodeficiency virus type 1. J Virol 72:772-777.
271. Zastre J, Chan GNY, Ronaldson PT, Ramaswamy M, Bendayan R. 2007. P-glycoprotein mediated transport and induction by the HIV-1 protease inhibitor atazanavir in a human brain microvessel endothelial cell line. Can J Infect Dis 18:53B.
272. Zeng Y, Zhang X, Huang Z, Cheng L, Yao S, Qin D, Chen X, Tang Q, Lv Z, Zhang L, Lu C. 2007. Intracellular Tat of human immunodeficiency virus type 1 activates lytic cycle replication of Kaposi's sarcoma-associated herpesvirus: Role of JAK/STAT signaling. J Virol 81:2401-2417.
273. Zhang W, Mojsilovic-Petrovic J, Andrade MF, Zhang H, Ball M, Stanimirovic DB. 2003. The expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB J 17:2085- 2087.
274. Zhang Y, Schuetz JD, Elmquist WF, Miller DW. 2004. Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cells. J Pharmacol Exp Ther 311:449- 455.
275. Zhao ML, Kim MO, Morgello S, Lee SC. 2001. Expression of inducible nitric oxide synthase, interleukin-1 and caspase-1 in HIV-1 encephalitis. J Neuroimmunol 115:182-191.
276. Zheng J, Thylin MR, Ghorpade A, Xiong H, Persidsky Y, Cotter R, Niemann D, Che M, Zeng YC, Gelbard HA, Shepard RB, Swartz JM, Gendelman HE. 1999. Intracellular CXCR4 signaling, neuronal apoptosis and neuropathogenic mechanisms of HIV-1-associated dementia. J Neuroimmunol 98:185-200.
277. Zhou BY, Liu Y, Kim B, Xiao Y, He JJ. 2004. Astrocyte activation and dysfunction and neuron death by HIV-1 Tat expression in astrocytes. Mol Cell Neurosci 27:296-305.
278. Zhou J, Liu M, Aneja R, Chandra R, Lage H, Joshi HC. 2006. Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer Res 66:445-452.
279. Zhou W, Cayabyab FS, Pennefather PS, Schlichter LC, DeCoursey TE. 1998. HERG-like K1 channels in microglia. J Gen Physiol 111:781-794.